SUNNYVALE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Accuray Incorporated , a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place November 1 - 5 in Chicago, Illinois. This represents a 27 percent increase in CyberKnife abstracts over last year's Annual Meeting.
The accepted abstracts, which will be presented as posters or oral presentations, focus on the use of the CyberKnife® Robotic Radiosurgery System to treat tumors located throughout the body including the prostate, lung, brain, spine, liver, pancreas, head and neck.
"The depth and breadth of research presented at this year's ASTRO meeting is a testament to the growing clinical acceptance of the CyberKnife System and the important role it is playing in the treatment of cancer," said Euan Thomson, Ph.D., president and CEO of Accuray.
Highlights of the research that will be showcased include seven presentations focusing on the use of CyberKnife radiosurgery to treat prostate cancer. CyberKnife prostate procedures from July-September 2009 increased 21 percent over the same period the previous year, confirming the increasing demand for this treatment option. To date, CyberKnife radiosurgery has been used to treat more than 4,000 men with prostate cancer.
Additionally, Accuray will host a number of presentations in the company's booth (#1526) reporting on experience with CyberKnife radiosurgery. Presenters include Eric Lartigau, M.D., Ph.D., from Centre Oscar Lambret; Xiaodong Wu, Ph.D., from University of Miami; Donald B. Fuller, M.D., from CyberKnife Centers of San Diego; Brian T. Collins, M.D., from Georgetown University Hospital; Joe Y. Chang, M.D., Ph.D., from M. D. Anderson Cancer Center; Debra Freeman, M.D., from Naples Radiation Oncology; Sonja Dieterich, Ph.D., and Iris Gibbs, M.D., from Stanford University Hospital; Kim Huang, M.D., from University of California San Francisco; and Greg Spurlock from US Radiosurgery.
Accuray will be exhibiting at booth #1526. For more information on the accepted abstracts, posters and in-booth presentations related to the CyberKnife System please visit http://www.accuraychicago.com/.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated , based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 180 Systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com/.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to publication of clinical results, clinical acceptance of products, and growing demand for treatments are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2009 fiscal year and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D. https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869 Omar Dawood, M.D., MPH https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85068
Accuray Incorporated
CONTACT: Stephanie Tomei, Senior Manager, Marketing Communications of
Accuray Incorporated, +1-408-789-4234, stomei@accuray.com; or Brianne Donahue
of Schwartz Communications, +1-415-817-2545, accuray@schwartz-pr.com, for
Accuray Incorporated
Web Site: http://www.accuray.com/
http://www.accuraychicago.com/
